Hagop Kantarjian
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Hagop Kantarjian
May 15, 2024, 14:47 |
Drugs
Hagop Kantarjian: New research is expanding inotuzumab use into frontline, for MRD+, and in combination with blinatumomab
Nicholas Short, Associate Professor at the Department of Leukemia at MD Anderson Cancer Center, shared…
May 12, 2024, 07:56 |
Dialogues
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Join us for an exciting new episode of “OncoInfluencers”, hosted by Dr. Gevorg Tamamyan. In this episode, we…
Apr 26, 2024, 08:09 |
Blog
Hagop Kantarjian: The results of the first clinical trial to explore activin receptor ligand traps of drugs in MF
Hagop Kantarjian, Leukaemia professor and Chair at MD Anderson Cancer Center, shared on X: ''Activin receptor…
Apr 21, 2024, 21:27 |
Drugs
Hagop Kantarjian: We review the evidence leading to Tagraxofusp approval as first in class CD123-directed drug which has changed the field of BPDCN
Hagop Kantarjian, Leukaemia professor and Chair at MD Anderson Cancer Center, shared on X: “Tazgraxofusp is…
Apr 20, 2024, 07:03 |
Drugs
Hagop Kantarjian: Dasatinib and Venetoclax is safe and effective in newly diagnosed CML in CP
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Apr 5, 2024, 08:22 |
Insight
Hagop Kantarjian: Low-dose azacitidine plus venetoclax - in patients with AML unable to complete standard consolidation strategies
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Mar 10, 2024, 20:49 |
Insight
Hagop Kantarjian: In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia
Hagop Kantarjian, a Professor and Chair of the Department of Leukemia at The University…
Mar 4, 2024, 10:16 |
Blog
Hagop Kantarjian: Gamma delta T cells, a novel immunotherapy for AML
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD…
Feb 21, 2024, 20:45 |
Blog
Peter Pisters: Delighted to drop by MD Anderson Cancer Center's Leukemia faculty to discuss the exceptional breakthroughs over the years
Peter Pisters, President at MD Anderson Cancer Center, shared on LinkedIn: “Delighted to drop by…
Feb 18, 2024, 15:51 |
Blog
Hagop Kantarjian: In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate
Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer…
1
2
3
4
All:
35
Posts:
1 - 10
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Barbara Jereczek-Fossa has been elected as the ESTRO President-elect!
Facebook
RSS Feed
Twitter
Linkedin
Youtube